Sodium–glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines-Reference-Cited by-同舟云学术

Sodium–glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines

Published:2022-08 Issue:8 Volume:36 Page:108257
ISSN:1056-8727
Container-title:Journal of Diabetes and its Complications
language:en
Short-container-title:Journal of Diabetes and its Complications

Author:

Stougaard Elisabeth B.,Rossing Peter,Cherney David,Vistisen Dorte,Persson Frederik

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference47 articles.

1. All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992–1999;Soedamah-Muthu;Diabetologia,2006

2. Clinical practice guideline for diabetes management in chronic kidney disease;KDIGO;Kidney Int,2020

3. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group;Lewis;N Engl J Med,1993

4. Effects of SGLT2 inhibitors on kidney and cardiovascular function;Vallon;Annu Rev Physiol,2021

5. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial;Dandona;Lancet Diabetes Endocrinol,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of Sodium-Glucose Cotransporter Inhibitors in Type 1 Diabetes: The Promise and the Perils;Endocrine Practice;2024-06

2. Combination therapy for kidney disease in people with diabetes mellitus;Nature Reviews Nephrology;2024-04-03

3. Effect of sodium‐glucose cotransporter 2 inhibitor canagliflozin on interstitial glucose concentration in insulin‐treated diabetic dogs;Journal of Veterinary Internal Medicine;2024-03-25

4. Diabetic kidney disease in type 1 diabetes: challenges and differences from type 2 diabetes;Metabolism;2024-02

5. Real-world safety and effectiveness of dapagliflozin in people living with type 1 diabetes in Spain: The Dapa-ON multicenter retrospective study;Diabetes & Metabolism;2024-01